4672-18-8

Basic information

• Product Name: 4-piperidinobutyronitrile
• Synonyms: 1-Piperidinebutyronitrile;1-Piperidinebutanenitrile
• CAS NO: 4672-18-8
• Molecular Formula: C₉H₁₆N₂
• Molecular Weight: 152.2367
• EINECS: 225-119-7
• Mol File: 4672-18-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 268.8°C at 760 mmHg
• Flash Point: 109.6°C
• Appearance: /
• Density: 0.942g/cm³
• Vapor Pressure: 0.00752mmHg at 25°C
• Refractive Index: 1.47
• CAS DataBase Reference: 4-piperidinobutyronitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-piperidinobutyronitrile(4672-18-8)
• EPA Substance Registry System: 4-piperidinobutyronitrile(4672-18-8)

Safety Data

• Hazardous Substances Data: 4672-18-8(Hazardous Substances Data)

Usage

General Description

4-piperidinobutyronitrile is a chemical compound that is a derivative of piperidine, a heterocyclic organic compound. It is commonly used in the synthesis of pharmaceuticals and agrochemicals as a building block. Its chemical structure consists of a piperidine ring attached to a butyronitrile group, making it useful in the creation of various complex molecules. 4-piperidinobutyronitrile is also known for its role as an intermediate in the production of other important chemical compounds. Additionally, it has been studied for its potential use in the development of new drugs and materials due to its versatile properties and reactivity.

InChI:InChI=1/C9H16N2/c10-6-2-5-9-11-7-3-1-4-8-11/h1-5,7-9H2

Upstream product

• 110-89-4 piperidine 
• 17790-82-8 3-cyanopropanoyl chloride 
• 5332-06-9 4-bromobutanenitrile 
• 110-91-8 morpholine 
• 1027379-53-8 cyano acrylate 
• 628-20-6 4-Chlorobutyronitrile 

Downstream Products

• 4672-16-6 4-piperidin-1-ylbutanoic acid 

Relevant articles and documents

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS

The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.